The effect of colesevelam treatment on bile acid and lipid metabolism and glycemic control in healthy men.
Abstract
The treatment of hypercholesterolemia with bile acid (BA) sequestrants results in upregulation of BA synthesis through the classical pathway initiated by cholesterol 7alpha-hydroxylase (CYP7A1). To characterize the detailed dynamics of serum lipid and BA concentrations and the BA synthesis rate in response to treatment with BA sequestrants and to determine whether the -203A/C promoter polymorphism of the CYP7A1 encoding gene (CYP7A1) affects such a response, this pilot study was carried out in healthy men (8 homozygous for the -203A allele and 8 homozygous for the -203C allele of CYP7A1). The subj...
Source: Physiological Research - August 18, 2016 Category: Physiology Authors: Blahová T, Peterková L, Leníček M, Vlachová M, Zemánková K, Adámková V, Vítek L, Kovář J Tags: Physiol Res Source Type: research
Colesevelam as an Add-On Treatment for Control of Dyslipidemia and Hyperglycemia in Type 2 Diabetes
Publication date: April 2016 Source:Canadian Journal of Diabetes, Volume 40, Issue 2 Author(s): Supna Sandhu, Mandana Moosavi, Kamran Golmohammadi, Gordon A. Francis (Source: Canadian Journal of Diabetes)
Source: Canadian Journal of Diabetes - March 30, 2016 Category: Endocrinology Source Type: research
Effect of chenodeoxycholic acid and the bile acid sequestrant colesevelam on glucagon‐like peptide‐1 secretion
ConclusionsCDCA increased GLP‐1 and glucagon secretion, and delayed gastric emptying. We speculate that bile acid‐induced activation of TGR5 on L cells increases GLP‐1 secretion, which, in turn, may result in amplification of glucose‐stimulated insulin secretion. Furthermore our data suggest that colesevelam does not have an acute effect on GLP‐1 secretion in humans. (Source: Diabetes, Obesity and Metabolism)
Source: Diabetes, Obesity and Metabolism - March 21, 2016 Category: Endocrinology Authors: M. Hansen, M. J. Scheltema, D. P. Sonne, J. S. Hansen, M. Sperling, J. F. Rehfeld, J. J. Holst, T. Vilsbøll, F. K. Knop Tags: ORIGINAL ARTICLE Source Type: research
Novel pharmacological therapies for irritable bowel syndrome.
This article reviews the novel pharmacological treatments already or recently approved for patients with IBS-C (lubiprostone, linaclotide) and IBS-D (alosetron, ramosetron, rifaximin, eluxadoline). Furthermore, results for drugs in development (plecanatide, ibudutant and ebastine) or used in chronic constipation or for other indications, with potential application in IBS (prucalopride, elobixibat, mesalazine, ondansetron and colesevelam) are also reviewed.
PMID: 26907518 [PubMed - as supplied by publisher] (Source: Expert Review of Gastroenterology and Hepatology)
Source: Expert Review of Gastroenterology and Hepatology - February 26, 2016 Category: Gastroenterology Tags: Expert Rev Gastroenterol Hepatol Source Type: research
Exploring the management of statin intolerant patients: 2016 and beyond.
Abstract
Statins remain the cornerstone of lipid-lowering treatment.They significantly reducing cardiovascular morbidity and mortality in primary and secondary prevention settings. Statin-treated patients may present adverse events (clinical and/or biochemical) that can lead to treatment discontinuation or a reduction in the dose of statins. Statin intolerance may appear at any time during the treatment. In each case, secondary causes should be assessed and treated and lifestyle measures should be implemented. Up to 3 different statins can be tried at a low dose; statin dosing every-other-day or once weekl...
Source: Current Vascular Pharmacology - February 26, 2016 Category: Drugs & Pharmacology Authors: Katsiki N, Athyros VG, Karagiannis A Tags: Curr Vasc Pharmacol Source Type: research
Review article: bile acid diarrhoea – pathogenesis, diagnosis and management
ConclusionBile acid diarrhoea is common, and likely under‐diagnosed. Bile acid diarrhoea should be considered relatively early in the differential diagnosis of chronic diarrhoea. (Source: Alimentary Pharmacology and Therapeutics)
Source: Alimentary Pharmacology and Therapeutics - February 24, 2016 Category: Drugs & Pharmacology Authors: N. Mottacki, M. Simrén, A. Bajor Tags: Review Article Source Type: research
The effect of chenodeoxycholic acid and the bile acid sequestrant colesevelam on glucagon‐like peptide‐1 secretion
ConclusionsCDCA increased GLP‐1 and glucagon secretion, and delayed gastric emptying. We speculate that bile acid‐induced activation of TGR5 on L cells increases GLP‐1 secretion, which in turn may result in amplification of glucose‐stimulated insulin secretion. Furthermore our data suggest that colesevelam does not have an acute effect on GLP‐1 secretion in humans. (Source: Diabetes, Obesity and Metabolism)
Source: Diabetes, Obesity and Metabolism - February 17, 2016 Category: Endocrinology Authors: Morten Hansen, Matthijs J. Scheltema, David P. Sonne, Jakob S. Hansen, Michael Sperling, Jens F. Rehfeld, Jens J. Holst, Tina Vilsbøll, Filip K. Knop Tags: ORIGINAL ARTICLE Source Type: research
Patient tolerance and acceptance of colesevelam hydrochloride: focus on type-2 diabetes mellitus.
Authors: Brunetti L, DeSantis EH
Abstract
Diabetes mellitus (DM) is a chronic disease with a U.S. prevalence of 25.8 million, and 90-95% of all cases are type-2 diabetes mellitus (T2DM). Despite the known mortality and morbidity associated with T2DM, the majority of patients do not achieve their hemoglobin A1c (HbA1c) goals. Nonadherence is one of the contributing factors to the lackluster attainment of treatment goals. Drug tolerability may impact medication nonadherence; therefore, strategies to improve tolerability are important. Colesevelam, a second-generation bile acid resin, was designed with greate...
Source: P and T - December 12, 2015 Category: Drugs & Pharmacology Tags: P T Source Type: research
An evidence‐based review of systemic treatments for itch
ConclusionsThe findings from this study suggest the effective therapeutic approaches for itch. The major limitations are that there are small numbers of available RCTs and methodological differences across studies. (Source: European Journal of Pain)
Source: European Journal of Pain - September 29, 2015 Category: Anesthesiology Authors: P. Pongcharoen, A.B. Fleischer Tags: Mini Review Source Type: research
Nonstatin Therapies for Management of Dyslipidemia: A Review.
Abstract
PURPOSE: Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the United States. Recently published cholesterol treatment guidelines emphasize the use of statins as the preferred treatment strategy for both primary and secondary prevention of CVD. However, the optimal treatment strategy for patients who cannot tolerate statin therapy or those who need additional lipid-lowering therapy is unclear in light of recent evidence that demonstrates a lack of improved cardiovascular outcomes with combination therapy. The purpose of this review is to summarize and interpret eviden...
Source: Clinical Therapeutics - September 24, 2015 Category: Drugs & Pharmacology Authors: Sando KR, Michelle Knight P Tags: Clin Ther Source Type: research
Effect of Bile Acid Sequestrants on the Risk of Cardiovascular Events: A Mendelian Randomization Analysis [Original Articles]
Conclusions—
The cholesterol lowering effect of BAS may translate into a clinically relevant reduction in CAD. (Source: Circulation: Cardiovascular Genetics)
Source: Circulation: Cardiovascular Genetics - August 18, 2015 Category: Cardiology Authors: Ross, S., D'Mello, M., Anand, S. S., Eikelboom, J., CARDIoGRAMplusC4D Consortium, Stewart, A. F. R., Samani, N. J., Roberts, R., Pare, G. Tags: Cardiovascular Pharmacology, Secondary prevention, Acute coronary syndromes, Genetics of cardiovascular disease Original Articles Source Type: research
Cryptogenic diarrhea
A number of ordinary conditions can trigger chronic diarrhea. Yet none were to blame in the case of a 58-year-old, thin, Caucasian woman who reported worsening of the persistent diarrhea that followed her gastric bypass surgery. Treatment with colesevelam had been providing moderate control of the condition. She also had a history of chronic kidney disease and tracheal stenosis secondary to prolonged intubation after a cerebrovascular accident, which had occurred many years earlier. (Source: The American Journal of Medicine)
Source: The American Journal of Medicine - July 16, 2015 Category: Journals (General) Authors: Mercy Tomy Tags: Diagnostic Dilemma Source Type: research
Quantifying bile acid malabsorption helps predict response and tailor sequestrant therapy.
Abstract
Although recognised as a cause of chronic diarrhoea for over forty years, diagnostic tests and treatments for bile acid malabsorption (BAM) remain controversial. Recent National Institute for Health and Care Excellence (NICE) guidelines highlighted the lack of evidence in the field, and called for further research. This retrospective study explores the BAM subtype and severity, the use and response to bile acid sequestrants (BAS) and the prevalence of abnormal colonic histology. 264 selenium-75-labelled homocholic acid conjugated taurine (SeHCAT)-tested patient records were reviewed and the severi...
Source: Clinical Medicine - June 1, 2015 Category: Journals (General) Authors: Orekoya O, McLaughlin J, Leitao E, Johns W, Lal S, Paine P Tags: Clin Med Source Type: research
Bile Acid diarrhea: prevalence, pathogenesis, and therapy.
Authors: Camilleri M
Abstract
Bile acid diarrhea (BAD) is usually seen in patients with ileal Crohn's disease or ileal resection. However, 25% to 50% of patients with functional diarrhea or diarrhea-predominant irritable bowel syndrome (IBS-D) also have evidence of BAD. It is estimated that 1% of the population may have BAD. The causes of BAD include a deficiency in fibroblast growth factor 19 (FGF-19), a hormone produced in enterocytes that regulates hepatic bile acid (BA) synthesis. Other potential causes include genetic variations that affect the proteins involved in BA enterohepatic circulation and syn...
Source: Gut and Liver - April 30, 2015 Category: Gastroenterology Tags: Gut Liver Source Type: research
Lipid Target Achievement Among Patients With Very High and High Cardiovascular Risk in a Lipid Clinic
This was a retrospective study that assessed achievement of lipid-lowering treatment targets in the setting of a University Hospital Lipid Clinic. Low-density lipoprotein cholesterol (LDL-C) goal attainment according to National Cholesterol Education Program-Adult Treatment Panel III (NCEP ATP III) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines was recorded in 1000 consecutive adult patients followed for ≥3 years (mean 8 years). The LDL-C targets according to the NCEP ATP III were attained by 66% and 86% of patients with "very high" (n = 477) and "high" (n = 408) cardiovascular ...
Source: Angiology - April 9, 2015 Category: Cardiology Authors: Barkas, F., Liberopoulos, E. N., Kostapanos, M. S., Liamis, G., Tziallas, D., Elisaf, M. Tags: Lipids Source Type: research
